Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227173 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Drug-drug Interaction Study in Healthy Volunteers
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02227173 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 20 participants.
The verdict
NCT02227173, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-label, single-sequence, drug-drug interaction study in healthy male and female subjects. There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-986020 with montelukast, flurbiprofen, and digoxin may increase the exposure of montelukast, flurbiprofen, and digoxin.
Interventions
- DRUG Montelukast
- DRUG Digoxin
- DRUG BMS-986020
- DRUG Flurbiprofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-09 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02227173
The ClinicalTrials.gov registry entry for NCT02227173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Montelukast is the first listed.
NCT02227173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02227173 about?
NCT02227173 is a clinical study titled "A Phase 1 Drug-drug Interaction Study in Healthy Volunteers". This is an open-label, single-sequence, drug-drug interaction study in healthy male and female subjects. There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-986020 with montelukast, flurbiprofen, and digoxin may increase the exposure of mont...
What is the current status of trial NCT02227173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-09. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02227173?
The interventions under investigation include: Montelukast (DRUG), Digoxin (DRUG), BMS-986020 (DRUG), Flurbiprofen (DRUG).
Who is sponsoring clinical trial NCT02227173?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.